Conor Medsystems Announces Decision from U.K. High Court of Justice
February 24 2006 - 8:45AM
PR Newswire (US)
Ruling Invalidates Angiotech Patent on Paclitaxel Coated Stents
MENLO PARK, Calif., Feb. 24 /PRNewswire-FirstCall/ -- Conor
Medsystems, Inc. (NASDAQ:CONR) announced that the High Court of
Justice in the United Kingdom today handed down its decision in
Conor's lawsuit to invalidate EP 0 706 376 to Angiotech
Pharmaceuticals, Inc. The patent is exclusively licensed to Boston
Scientific Corporation for use in the field of coronary stents. Mr.
Justice Pumfrey ruled that Angiotech's patent is invalid for
obviousness over three separate prior art references. About Conor
Medsystems Conor Medsystems, Inc. develops innovative controlled
vascular drug delivery technologies, and has initially focused on
the development of drug eluting stents to treat coronary artery
disease. For further information on Conor Medsystems and controlled
vascular delivery, visit http://www.conormed.com/. DATASOURCE:
Conor Medsystems, Inc. CONTACT: investors, Michael Boennighausen,
Chief Financial Officer, of Conor Medsystems, Inc., +1-650-614-4100
Web site: http://www.conormed.com/
Copyright
Conor Medsystems (NASDAQ:CONR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Conor Medsystems (NASDAQ:CONR)
Historical Stock Chart
From Jul 2023 to Jul 2024